3 Reasons I Bought AMC Stock This Month

AMC shares are up 58% year-to-date as theatrical attendance and major film releases recover, though the stock remains down 99.5% on a split-adjusted basis over five years after roughly 50-fold dilution since 2019. AMC trades at 1.7x trailing revenue versus Cinemark's 1.9x despite 56% higher trailing revenue, but is not expected to return to annual profitability until 2028. The bullish thesis centers on high-margin concessions—81% gross margin and greater gross profit than admissions in the latest quarter—plus 1.1 million AMC Stubs A-List members and expanding ancillary revenue initiatives.

Analysis

AMC’s equity remains a residual claim on a highly levered operating recovery, not a clean exhibition-cycle long. Incremental attendance disproportionately improves cash generation through concessions and advertising, but the same recovery also increases AMC’s ability—and incentive—to issue equity or refinance expensive obligations; any valuation discount to CNK is therefore appropriately partly structural. A sustained box-office slate can support a 1-3 month momentum trade, yet AMC needs materially better EBITDA-to-interest coverage before its multiple can converge with CNK or IMAX.

The cleaner beneficiaries of a longer theatrical-window normalization are IMAX and CNK. IMAX captures premium-format mix with an asset-light, international royalty profile and less balance-sheet optionality; CNK converts attendance into equity value more directly because fewer dollars are absorbed by financing costs. NFLX’s selective theatrical releases are more likely a marketing and awards-spend optimization than evidence of a broad strategic reversal, so the read-through to exhibitors should not be extrapolated from isolated prestige titles.

Consensus enthusiasm is likely underestimating supply volatility: a few strong releases do not repair the multi-year production pipeline disrupted by labor stoppages and studio cost cuts. The decisive data are domestic admissions, per-patron concession spend, adjusted EBITDA, and net-debt reduction—not global box office or membership counts. A weak post-holiday slate, softer concession per-capita spending, or renewed AMC share issuance would quickly invalidate the recovery-multiple narrative.

Near term, AMC can remain squeeze-sensitive given retail participation and improving industry sentiment, making outright shorts hazardous around blockbuster weekends. Over 6-18 months, however, the likely divergence is operationally stronger exhibitors compounding while AMC’s capital structure captures much of the recovery; the market should value AMC on dilution-adjusted free-cash-flow capacity rather than revenue scale.

Key Decisions for Investors

• Prefer a 6-12 month long IMAX / short AMC pair, sized beta-neutral: IMAX offers premium-format and international upside while AMC carries refinancing and dilution risk. Reassess if AMC demonstrates two consecutive quarters of positive free cash flow after interest and no new equity issuance.
• For broad exhibition exposure, accumulate CNK on post-release-window pullbacks rather than chase AMC momentum. Target a 1-3 quarter holding period; exit or reduce if domestic attendance disappoints materially versus the holiday slate or CNK’s EBITDA margin fails to expand with volume.
• Treat AMC as a tactical, small-risk event trade only around verifiable attendance catalysts, preferably via defined-risk call spreads rather than common equity. Do not convert to a strategic long absent evidence that adjusted EBITDA covers cash interest with room for debt reduction.
• Monitor AMC’s share count, debt-exchange terms, liquidity runway, and quarterly concession spend per patron as hard alerts. Any equity issuance or liability-management transaction that transfers value to creditors should be viewed as a catalyst to increase the IMAX/CNK-over-AMC relative-value trade.